

**Table 9. Half-width confidence interval summary for estimated difference between dual-frame and single-frame estimates for select vaccines, NIS-Child, 2016-2017\***

	All Estimation Areas Including Territories				All Estimation Areas Excluding Territories			
	2016		2017		2016		2017	
	Mean	Median	Mean	Median	Mean	Median	Mean	Median
<b>DTaP<sup>†</sup></b>								
≥3 doses	1.03	1.00	0.77	0.50	1.03	1.00	0.77	0.50
≥4 doses	1.82	1.70	1.69	1.60	1.82	1.70	1.69	1.60
<b>Poliovirus (≥3 doses)</b>	1.13	1.10	0.86	0.70	1.13	1.10	0.86	0.70
<b>MMR (≥1 dose)<sup>¶</sup></b>	1.28	1.10	0.90	0.70	1.28	1.10	0.90	0.70
<b>Hib<sup>**</sup></b>								
Primary series	1.22	1.10	0.97	0.75	1.22	1.10	0.97	0.75
Full series	1.79	1.70	1.70	1.55	1.79	1.70	1.70	1.55
<b>HepB</b>								
≥3 doses	1.10	0.90	1.11	0.85	1.10	0.90	1.11	0.85
Birth dose <sup>††</sup>	2.12	1.90	1.99	1.85	2.12	1.90	1.99	1.85
<b>Varicella (≥1 dose)<sup>¶</sup></b>	1.32	1.30	0.99	0.80	1.32	1.30	0.99	0.80
<b>PCV</b>								
≥3 doses	1.18	1.10	0.92	0.70	1.18	1.10	0.92	0.70
≥4 doses	1.87	1.70	1.60	1.40	1.87	1.70	1.60	1.40
<b>HepA</b>								
≥1 dose	1.59	1.50	1.46	1.40	1.59	1.50	1.46	1.40
≥2 doses <sup>§§</sup>	2.38	2.20	2.26	2.00	2.38	2.20	2.26	2.00
<b>Rotavirus<sup>¶¶</sup></b>	2.13	2.00	2.11	1.95	2.13	2.00	2.11	1.95
<b>Combined 7-vaccine series<sup>***</sup></b>	2.19	2.10	2.09	1.85	2.19	2.10	2.09	1.85
<b>No vaccinations</b>	0.23	0.00	0.18	0.00	0.23	0.00	0.18	0.00

**Abbreviations:** CI = confidence interval; DTaP = diphtheria, tetanus toxoids, and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; MMR = measles, mumps, and rubella vaccine; PCV = pneumococcal conjugate vaccine.

\* For 2016, children born during January 2013–May 2015 and for 2017, children born during January 2014–May 2016.

† Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria, tetanus toxoids, and pertussis vaccine.

§ Statistically significantly different from 0 at  $p < 0.05$ .

¶ Includes children who may have been vaccinated with measles, mumps, rubella, and varicella combination vaccine.

\*\* Hib primary series: receipt of  $\geq 2$  or  $\geq 3$  doses, depending on product type received; full series: primary series and booster dose, which includes receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product type received.

†† One dose of HepB administered from birth through age 3 days.

§§ Estimates of  $\geq 2$  doses of HepA are likely underestimates because a child could be on schedule but not receive a second dose of HepA until age 41 months. This dose would not be collected by NIS-Child, which includes children aged 19–35 months only.

¶¶ Includes  $\geq 2$  doses of Rotarix monovalent rotavirus vaccine (RV1), or  $\geq 3$  doses of RotaTeq pentavalent rotavirus vaccine (RV5). The maximum age for the final rotavirus dose is 8 months, 0 days.

\*\*\* The combined 7-vaccine series (4:3:1:3\*:3:1:4) includes  $\geq 4$  doses of DTaP,  $\geq 3$  doses of poliovirus vaccine,  $\geq 1$  dose of measles-containing vaccine, the full series of Hib ( $\geq 3$  or  $\geq 4$  doses, depending on product type),  $\geq 3$  doses of HepB,  $\geq 1$  dose of varicella vaccine, and  $\geq 4$  doses of PCV.